Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHIU BIN HSIAO

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1699714170
CMS profile
696466
Location
PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$11,760.00

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
ViiV Healthcare Company $11,760.00 6

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHIU BIN HSIAO

NPI 1699714170 · CMS profile ID 696466

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699714170?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHIU BIN HSIAO, NPI 1699714170, CMS profile ID 696466. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699714170?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). CHIU BIN HSIAO, NPI 1699714170, CMS profile ID 696466. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699714170?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
CHIU BIN HSIAO, NPI 1699714170, CMS profile ID 696466, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1699714170?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $11,760.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ViiV Healthcare Company $1,200.0009/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803241247 CMS
ViiV Healthcare Company $1,200.0005/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803240877 CMS
ViiV Healthcare Company $1,200.0004/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803238147 CMS
ViiV Healthcare Company $2,760.0004/27/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803237577 CMS
ViiV Healthcare Company $4,200.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803237373 CMS
ViiV Healthcare Company $1,200.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803241259 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $9,919.33 17
PY2020 $9,740.00 4
PY2021 $11,760.00 6
PY2022 $1,331.47 2
PY2024 $65.32 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $203,074.99 20
PY2024 Principal investigator $83,951.54 5
PY2023 Principal investigator $754,820.99 35
PY2022 Principal investigator $86,831.87 28
PY2021 Principal investigator $112,718.29 59
PY2020 Principal investigator $137,247.57 55
PY2019 Principal investigator $149,847.03 58

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

55 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Gilead Sciences, Inc. $1,129.00 12/23/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 742088127
Principal investigator 1 Gilead Sciences, Inc. $875.00 12/14/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 742088125
Principal investigator 1 Gilead Sciences, Inc. $75.00 12/07/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077643
Principal investigator 1 Gilead Sciences, Inc. $750.00 11/18/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077639
Principal investigator 1 Gilead Sciences, Inc. $2,816.00 11/18/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077641
Principal investigator 1 Gilead Sciences, Inc. $1,129.00 11/18/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 742088123
Principal investigator 1 ViiV Healthcare Company $150.00 11/18/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733427709
Principal investigator 1 ViiV Healthcare Company $1,290.00 11/18/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733427711
Principal investigator 1 ViiV Healthcare Company $430.00 11/18/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733427715
Principal investigator 1 Gilead Sciences, Inc. $1,575.00 11/16/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077635
Principal investigator 1 Gilead Sciences, Inc. $1,725.00 11/16/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077637
Principal investigator 1 ViiV Healthcare Company $860.00 11/13/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733427701
Principal investigator 1 ViiV Healthcare Company $215.00 11/13/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733427705
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 11/09/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 742088121
Principal investigator 1 ViiV Healthcare Company $1,290.00 11/09/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733427695
Principal investigator 1 ViiV Healthcare Company $215.00 11/09/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733427699
Principal investigator 1 ViiV Healthcare Company $16,963.25 10/27/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733427231
Principal investigator 1 Gilead Sciences, Inc. $1,129.00 10/21/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 742088119
Principal investigator 1 Gilead Sciences, Inc. $750.00 10/12/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077631
Principal investigator 1 Gilead Sciences, Inc. $750.00 10/12/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077633
Principal investigator 1 Gilead Sciences, Inc. $800.00 10/12/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 742088117
Principal investigator 1 Gilead Sciences, Inc. $516.00 09/23/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077627
Principal investigator 1 Gilead Sciences, Inc. $1,365.00 09/23/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077629
Principal investigator 1 Gilead Sciences, Inc. $2,250.00 09/16/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 742088115
Principal investigator 1 ViiV Healthcare Company $2,150.00 09/03/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733427045
Principal investigator 1 ViiV Healthcare Company $225.00 08/28/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733425805
Principal investigator 1 ViiV Healthcare Company $1,000.00 08/28/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733425809
Principal investigator 1 Gilead Sciences, Inc. $860.00 08/19/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077623
Principal investigator 1 Gilead Sciences, Inc. $2,547.00 08/19/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077625
Principal investigator 1 Gilead Sciences, Inc. $6,044.00 08/19/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 742088113
Principal investigator 1 Gilead Sciences, Inc. $250.00 08/17/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077621
Principal investigator 1 Gilead Sciences, Inc. $250.00 08/10/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077619
Principal investigator 1 Gilead Sciences, Inc. $800.00 08/10/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 742088111
Principal investigator 1 Gilead Sciences, Inc. $3,374.00 07/22/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 742088109
Principal investigator 1 Gilead Sciences, Inc. $250.00 07/15/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077617
Principal investigator 1 ViiV Healthcare Company $430.00 07/15/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733425021
Principal investigator 1 ViiV Healthcare Company $860.00 07/15/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733425025
Principal investigator 1 ViiV Healthcare Company $16,092.18 07/09/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733424969
Principal investigator 1 ViiV Healthcare Company $2,580.00 07/02/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733425013
Principal investigator 1 ViiV Healthcare Company $1,290.00 07/02/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733425017
Principal investigator 1 Gilead Sciences, Inc. $3,580.00 06/17/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077615
Principal investigator 1 Gilead Sciences, Inc. $917.00 05/20/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077613
Principal investigator 1 Gilead Sciences, Inc. $11,500.00 04/27/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 742088107
Principal investigator 1 Gilead Sciences, Inc. $860.00 03/18/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077609
Principal investigator 1 Gilead Sciences, Inc. $3,396.00 03/18/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/TenA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077611
Principal investigator 1 Gilead Sciences, Inc. $38.00 03/09/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077607
Principal investigator 1 ViiV Healthcare Company $1,000.00 03/06/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733423661
Principal investigator 1 ViiV Healthcare Company $215.00 03/06/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733423665
Principal investigator 1 ViiV Healthcare Company $860.00 03/06/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733423675
Principal investigator 1 Gilead Sciences, Inc. $16,500.00 03/02/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 742088105
Principal investigator 1 Gilead Sciences, Inc. $250.00 02/19/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077603
Principal investigator 1 Gilead Sciences, Inc. $250.00 02/19/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 742077605
Principal investigator 1 ViiV Healthcare Company $1,075.00 01/29/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733422441
Principal investigator 1 ViiV Healthcare Company $860.00 01/20/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733422437
Principal investigator 1 ViiV Healthcare Company $16,897.14 01/09/2020 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 733422979